Full Breakdown
Eli Lilly Holds Steady While Drug Stocks Falter
9/9/2026, 1:20:42 AM
Core Event
On a holiday-shortened trading week, the broader healthcare sector slipped after Novartis disclosed setbacks in multiple Phase 3 trials, including a lipoprotein(a)-lowering drug that failed to improve cardiovascular outcomes. Novartis shares fell 11%, and Amgen dropped roughly 9%, making the sector the biggest drag on the Dow Jones Industrial Average. In contrast, Eli Lilly’s stock declined only about 2%, reflecting relative resilience amid the downturn.
Background & Context
Lipoprotein(a) (Lp-a) is a cholesterol-carrying particle largely determined by genetics. While Novartis’ trial succeeded in reducing Lp-a levels, it did not translate into measurable cardiovascular benefit, prompting a sharp market reaction. Eli Lilly, like Amgen, is also developing an Lp-a-lowering therapy, but the company’s larger exposure to obesity-related products shields it from the immediate impact of the Lp-a trial failures.
Data & Statistics
- Novartis stock: -11%
- Amgen stock: ?-9% (largest Dow drag)
- Eli Lilly stock: -2%
- JPMorgan identified Lilly, Gilead and AbbVie as its three top ideas in U.S. large-cap biopharma, citing three revenue drivers: the international obesity market, an anticipated Medicare ramp, and the company’s pipeline.
Official Statements & Responses
JPMorgan analysts highlighted Lilly’s next-generation obesity candidates—retatrutide, a higher-efficacy agent, and the amylin-based eloralintide, which demonstrated tolerability and meaningful weight loss in Phase 2 trials. The analysts argued that these pipeline assets, together with broader obesity market growth and Medicare expansion, underpin the firm’s upside potential despite the sector-wide pullback.
Why It Matters
Lilly’s modest stock dip suggests investors view its diversified pipeline and obesity focus as a buffer against isolated trial disappointments. If the obesity drugs continue to progress, the company could capture a larger share of a market projected to expand globally, potentially offsetting risks tied to cardiovascular-focused programs.
